Benzinga··Vandana SinghAdagio Medical's Heart Device Shows 84% Shock Freedom in Pivotal Trial
$ADGM surges 11.92% after FULCRUM-VT trial shows 84% shock freedom, 59% arrhythmia freedom, supporting FDA Premarket Approval pathway for vCLAS ablation system.
ADGMFDA approvalclinical trial